Holly Uppal

DNP Doctor of Nursing Practice,  Charité - Universitätsmedizin Berlin 

Location: Africa

Consulting Services

Hospital-Pharmacy-Insurance Biostatistics Admin and Customer Support Legal Support Pharma-CRO-Device

Areas Of Interest

Carrier, Toxin Calcium Channel Agonists Irrigations, Gastric Extracts, Placental Syntaxin 5 Protein Starch Branching Enzyme Embryo Loss Analyses, Discriminant Metabolic Detoxification, Drug Ligand, c-mpl Neanderthal alpha-Crystallin B Chain Coarctations, Aortic Provider, Healthcare Receptor, Granulocyte-Macrophage Colony-Stimulating Factor Lymphofollicular Granuloma, Eosinophilic Viruses, Onyong nyong Ribosomal RNA, 5S beta Lactamase III Technology, High Cost

Professional Narrative

Dr. Holly Uppal was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Uppal has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Executive Director, Amgen 1996
Director Medicine, Harvard Med 2009

Education

Doctor of osteopathic medicine, Harvard Medical School 2003
Bachelor of science in nursing, Harvard Medical School 2008

Referees


Publications

Tang Z, Kong N, Zhang X, Liu Y, Hu P, Mou S, Liljeström P, Shi J, Tan W, Kim JS, Cao Y, Langer R, Leong KW, Farokhzad OC, Tao W. A materials-science perspective on tackling COVID-19. Nat Rev Mater. 2020;5(11):847-860. doi: 10.1038/s41578-020-00247-y. Epub 2020 Oct 14. PMID: 33078077; PMCID: PMC7556605.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, Zhang F. CRISPR- Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014 Oct 9;159(2):440-55. doi: 10.1016/j.cell.2014.09.014. Epub 2014 Sep 25. PMID: 25263330; PMCID: PMC4265475.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :